CLINICAL TRIAL article
Front. Oncol., 15 February 2021
Sec. Women's Cancer
Volume 10 - 2020 | https://doi.org/10.3389/fonc.2020.565384
RETRACTED: A Phase II, Single-Arm Study of Apatinib and Oral Etoposide in Heavily Pre-Treated Metastatic Breast Cancer
Nanlin Hu 1
Anjie Zhu 1,2
Yiran Si 1
Jian Yue 3
Xue Wang 3
Jiayu Wang 1
Fei Ma 1
Binghe Xu 1
Peng Yuan 3*
1. Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
2. Department of Breast Oncology, Peking University Cancer Hospital/Institute, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Beijing, China
3. Department of VIP Medical Services, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Summary
Citation
Hu N, Zhu A, Si Y, Yue J, Wang X, Wang J, Ma F, Xu B and Yuan P (2021) RETRACTED: A Phase II, Single-Arm Study of Apatinib and Oral Etoposide in Heavily Pre-Treated Metastatic Breast Cancer. Front. Oncol. 10:565384. doi: 10.3389/fonc.2020.565384
Received
19 October 2020
Accepted
14 December 2020
Published
15 February 2021
Retracted
10 February 2026
Volume
10 - 2020
Edited by
Hirokazu Tanino, Kobe University, Japan
Reviewed by
Caigang Liu, ShengJing Hospital of China Medical University, China; Dong-Xu Liu, Auckland University of Technology, New Zealand
Updates
This article was submitted to Women’s Cancer, a section of the journal Frontiers in Oncology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.